Premium
Ovarian suppression treatment prior to in‐vitro fertilization and embryo transfer in Chinese women with stage III or IV endometriosis
Author(s) -
Ma Caihong,
Qiao Jie,
Liu Ping,
Chen Guian
Publication year - 2008
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2007.08.021
Subject(s) - medicine , endometriosis , agonist , in vitro fertilisation , embryo transfer , gonadotropin releasing hormone agonist , luteal phase , gynecology , human fertilization , gonadotropin , andrology , gonadotropin releasing hormone , buserelin , hormone , embryo , luteinizing hormone , receptor , biology , anatomy , microbiology and biotechnology
Objective To evaluate the efficacy of a 2‐month treatment with a gonadotropin‐releasing hormone (GnRH) agonist prior to in‐vitro fertilization in Chinese women with moderate or severe endometriosis. Methods A study of 162 women surgically diagnosed as having moderate or severe endometriosis. Pituitary down‐regulation was achieved with injections of a GnRH agonist prior to the IVF procedures either for 7 to 10 days in the mid‐luteal phase (group 1 [standard protocol], 97 cycles in total), or for 2 months (group 2, 55 cycles), or 3 months (group 3, 75 cycles). Results Women pretreated with a GnRH agonist for 2 or 3 months required significantly higher doses of gonadotropin for ovarian stimulation ( P < 0.001), and for a longer time, than those treated with the standard long protocol ( P < 0.05). The number of oocytes and good embryos was lower in group 3 than in groups 1 or 2 ( P < 0.05). The implantation rate was significantly higher in group 2 than in group 1 ( P < 0.02). Conclusion A 2‐month treatment with a GnRH agonist prior to IVF produced a trend toward an increase in the implantation rate in a group of Chinese women with stages III and IV endometriosis.